Compare ULCC & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | CERT |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | 2020 |
| Metric | ULCC | CERT |
|---|---|---|
| Price | $6.54 | $7.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 10 |
| Target Price | $5.21 | ★ $11.67 |
| AVG Volume (30 Days) | 4.0M | ★ 4.6M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,724,000,000.00 | $418,838,000.00 |
| Revenue This Year | $23.76 | $4.18 |
| Revenue Next Year | $11.48 | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $3.02 | $4.45 |
| 52 Week High | $8.41 | $13.88 |
| Indicator | ULCC | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 46.61 | 69.31 |
| Support Level | $4.58 | $5.93 |
| Resistance Level | $6.66 | $7.46 |
| Average True Range (ATR) | 0.47 | 0.41 |
| MACD | -0.22 | 0.05 |
| Stochastic Oscillator | 11.94 | 94.46 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos, and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. The majority of revenue is from Domestic flight follow by International.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.